Latest 10-K annual reports

PMV Consumer Acquisition Corp. filed its 2025 10-K showing no revenues, a small net loss, OTC Pink trading, tight cash burn, and continued pursuit of a business opportunity, primarily in consumer products.

Allarity Therapeutics cut operating losses, resolved SEC matters, and advanced its PARP/tankyrase inhibitor stenoparib with Fast Track status and new trials while maintaining $14.7M cash at year-end.

eXoZymes reported a wider 2025 net loss, sharply lower cash, and a going concern warning while advancing its NCT program and winning new grants.

Clinical-stage radiopharma Aktis Oncology reported a $63.7M 2025 net loss, strengthened liquidity with a $335.3M January 2026 IPO and Lilly collaboration, and guided cash runway into 2029 as it advances Nectin-4 and B7-H3 programs.

Byrna Technologies amended its FY2025 annual report to add Part III disclosures, detail leadership changes, executive pay, ownership, governance policies, and auditor fees, with no financial statements updated.

Newly public fuel distributor reported 2025 results, launched a $2.00/share annual dividend, and used ~$207M IPO proceeds to reduce debt.

First Keystone posted 2025 net income of $6.2 million and stronger margins, but nonperforming assets jumped and a material weakness in internal controls was disclosed.

REX American Resources posted higher FY2025 net income on 45Z clean fuel tax credits, maintained strong cash, accelerated buybacks, and advanced a major carbon sequestration plan amid permitting delays.

BNY Mellon reports no material servicing noncompliance for 2025, KPMG issues clean attestation, and no material legal proceedings are disclosed for GJT.

BNY Mellon reports full Regulation AB servicing compliance for STRATS Trust 2006-2, with KPMG issuing a clean attestation and no material issues.

STRATS Trust for Procter & Gamble Securities, Series 2006-1 (NYSE: GJR) reported no material servicing noncompliance for 2025, with KPMG issuing an unqualified attestation of BNY Mellon’s trustee activities.

The travel-focused SPAC reported $3.9M 2025 net income driven by trust interest, holds $206.4M in its trust, and has until Feb. 16, 2027 to complete a business combination.

The STRATS Trust for Wal-Mart Stores, Inc. Series 2005-4 reported clean depositor/trustee compliance for 2025 with monthly distributions disclosed via Form 8-K and no legal proceedings.

Routine 10-K confirms clean trustee and CPA attestations, with 2025 distributions reported for the U.S. Cellular-backed STRATS Trust.

Newly launched multi-asset crypto ETF EZPZ reports $10.2M AUM, -9.67% NAV return, and tight index tracking with a 0.19% sponsor fee.

Photozou Holdings grew FY2024 revenue but widened net losses, flagged going-concern risks, raised equity, took a high-cost short-term loan, and plans a 2026 short drama launch after moving to exit used camera sales in 2025.

Electro-Sensors delivered record 2025 revenue of $10.1 million with higher gross margins, while net income declined on increased operating costs and lower interest income.

Steele Bancorp’s 2025 earnings jumped on the August 1 Northumberland Bancorp merger, aided by an $18.3M bargain purchase gain, while capital dipped into the CBLR grace period.

TechCom reported no operations or revenue in 2025, a $53,488 net loss, severe liquidity constraints, material control weaknesses, and plans to seek a merger target while relying on shareholder support for the next 12 months.

BioScience Health Innovations reported 2025 revenue up 208% to $5.69M and net income of $0.64M, detailed capital-raising and uplist plans, and disclosed material internal control weaknesses.

Lingerie Fighting Championships grew revenue 57% in 2025 and cut its net loss by 70%, but incurred a gross loss, carried heavy going‑concern doubts, multiple debt defaults, and large dilutive notes and warrants.

QHSLab delivered 26% revenue growth, positive net income, and eliminated over $1.4M of defaulted convertibles via repurchase, while warning of going-concern risks and material control weaknesses.

American Exceptionalism Acquisition Corp. A reported $348.4M in its trust following its $345M IPO, with no business combination yet and a 24–27 month window to close a deal.

Tempest Therapeutics closed a share-funded CAR‑T asset deal, reported striking early multiple myeloma data, and outlined 2026 milestones, but flagged a going‑concern risk with just $7.7M in cash and reliance on an uncertain funding commitment.

Allurion secured FDA PMA approval for its swallowable gastric balloon but reported a 53% revenue decline, going‑concern doubts, NYSE delisting proceedings, and tight liquidity as it restructures and pursues financings.

MeiraGTx reported $81.4M in 2025 revenue driven by a $75M Lilly upfront, narrowed its net loss to $114.2M, secured FDA Breakthrough for its xerostomia gene therapy, and extended liquidity into H2 2027 pending a $200M Hologen collaboration closing in Q2 2026.

Ondas Inc. posted an 8.5x jump in 2025 revenue to $50.7M, closed multiple acquisitions, raised over $800M, ended with $594M cash, and reported a $133.4M net loss driven partly by a large warrant liability.

Scienture Holdings reported a $41.5M FY25 loss amid $26.3M impairments, launched FDA‑approved ARBLI and secured U.S. rights to 10mg naloxone nasal spray REZENOPY.

Vor Biopharma refocused on autoimmune drug telitacicept, advanced two global Phase 3 trials, reported a $696.0M 2025 net loss driven by a $222.6M license charge and warrant revaluation, and announced a $75.0M private placement to extend cash runway into early 2029.

Entrepreneur Universe Bright Group grew revenue 7.7% and net income 28% in 2025, tightened cash to $11.0M, executed a 1-for-10 reverse split, and bought a Hong Kong money lender to enter fintech.